Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE demonstrated a positive financial outlook with a 13% year-over-year increase in product sales, rising from €144.6 million in 2023 to €163.3 million in 2024. The company reported total revenue of €169.6 million for 2024, marking a 10% increase from the previous year, and further projects substantial growth for its Ixchiq vaccine, estimating sales to surpass €100 million by its third year of launch. Additionally, with the FDA granting accelerated approval for Ixchiq, Valneva is well-positioned to capitalize on a global market for chikungunya vaccines expected to exceed $500 million annually, indicating strong future cash flow potential.

Bears say

Valneva SE is projected to experience a significant decrease in revenue estimates for 2025, declining from €222.5 million to €185 million, while also seeing a downward adjustment in its earnings per share estimate from (€0.53) to (€0.65). The company is attempting to reduce its operating cash burn to below €30 million by 2025, compared to over €60 million in 2024, highlighting ongoing financial strain. Additionally, projected sales for the Ixchiq vaccine have been lowered for fiscal year 2024 to €3 million, with long-term estimates also revised down from €250 million to €225 million for 2029, indicating challenges in meeting sales expectations.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.